COLL, US19459J1043

Collegium launches ADHD hub and Collegium stock sits at EUR 19.45

Published on 10/07/2026 at 00:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 6.00 percent to USD 199.9 million in the second quarter. Collegium stock sat at EUR 19.45 on October 6, 2026 versus EUR 19.45 prior close.

COLL, US19459J1043, Illustration mit AI erstellt.

Collegium Pharmaceutical (ISIN US19459J1043) had a Lang & Schwarz prior close of EUR 19.45 on October 6, 2026. On that date, StockTitan reported that Collegium launched Start Talking ADHD, an online resource hub with three downloadable guides for patients, families, healthcare providers and schools.

ADHD portfolio adds patient support

The October 6, 2026 launch extends Collegium's ADHD strategy beyond medicines into educational support. The guides cover doctor discussions, school support plans and personal support networks, while the company states that they do not diagnose ADHD or recommend a specific treatment.

The initiative follows Collegium's addition of a second ADHD medicine to its portfolio in May 2026, according to the same StockTitan release. For investors, the commercial test is whether the broader ADHD platform can offset pressure in Collegium's established pain portfolio.

Revenue grows while pain weakens

In the second quarter of 2026, Collegium reported total net product revenue of USD 199.9 million, up 6.00 percent year over year, according to Benzinga. Jornay PM revenue reached USD 46.1 million, a 41.00 percent year-over-year increase, while total Nucynta franchise revenue fell 24.00 percent to USD 35.2 million.

The same second-quarter report showed a GAAP net loss of USD 15.1 million, compared with GAAP net income of USD 12.0 million in the second quarter of 2025. Management guided to 2026 total product revenue of USD 825 million to USD 855 million, with adjusted EBITDA of USD 445 million to USD 470 million.

Analyst targets remain above the quote

MarketBeat reported that Oppenheimer began coverage on September 23, 2026, with an Outperform rating and a USD 50.00 price target. The same report said Needham reduced its target from USD 56.00 to USD 46.00 on August 6, 2026, while keeping a Buy rating.

Those targets are reported in US dollars and are separate from the euro reference price used for German investors. Collegium's market capitalization was USD 709.7 million as of October 6, 2026, giving the ADHD expansion and the weaker Nucynta pricing a direct valuation context.

Prior close sets the reference

Lang & Schwarz showed a prior close of EUR 19.45 for October 6, 2026. The Nasdaq listing is COLL, and the primary quotation currency is USD; the last structured quote for October 6 was USD 21.88, while the 52-week range was USD 21.43 to USD 50.79.

The further course of trading is shown by the continuously updated real-time quote of Collegium stock.